Systemic Lupus Erythematosus (SLE), a complex autoimmune disorder characterized by altered immune regulation, particularly involving B cells, which exhibit increased survival and developmental dysregulation. This study aimed to investigate the expression of IRF4, IRF8, SP1, and PU.1 in B cells of SLE patients, as these factors are known to play critical roles in the development, function, and differentiation of B cells.
Methods
B cells were isolated, cultured, and activated using anti-IgM. The mRNA expression of IRF4, IRF8, SP1, and PU.1 was assessed using reverse transcription polymerase chain reaction (RT-PCR) at baseline and after B cell activation. Correlations between transcription factor expression and clinical parameters were analyzed.
Results
Upon B cell activation, IRF4 expression increased significantly in SLE patients, unlike at baseline, where no changes were observed between groups. IRF8 expression was significantly raised in active SLE and increased upon activation. SP1 expression remained stable across all groups and conditions. PU.1 gene expression was higher in active SLE at baseline and increased further upon B cell activation. Positive correlations were found between IRF4 and IRF8, as well as between PU.1 and SP1. PU.1 expression correlated with SLE disease activity indices.
Conclusion
IRF4, IRF8, and PU.1 expression in B cells is altered in SLE. PU.1 shows a positive correlation with SLEDAI and anti-dsDNA titers. These findings highlight their potential roles in the pathogenesis of SLE in B cells.
TanakaY. Systemic lupus erythematosus. Best Pract Res Clin Rheumatol2022; 36(4): 101814.
2.
YapDYHChanTM. B cell abnormalities in systemic lupus erythematosus and lupus nephritis-role in pathogenesis and effect of immunosuppressive treatments. Int J Mol Sci2019; 20(24): 6231.
3.
CannySPJacksonSW. B cells in systemic lupus erythematosus: from disease mechanisms to targeted therapies. Rheum Dis Clin N Am2021; 47(3): 395–413.
4.
SzelinskiFLinoACDörnerT. B cells in systemic lupus erythematosus. Curr Opin Rheumatol2022; 34(2): 125–132.
5.
JenksSACashmanKSWoodruffMC, et al.Extrafollicular responses in humans and SLE. Immunol Rev2019; 288(1): 136–148.
6.
DiamantiAPRosadoMMCarsettiR, et al.B cells in SLE: different biological drugs for different pathogenic mechanisms. Autoimmun Rev2007; 7(2): 143–148.
7.
HardyRRHayakawaK. B cell development pathways. Annu Rev Immunol2001; 19: 595–621.
8.
DeguineJXavierRJ. B cell tolerance and autoimmunity: lessons from repertoires. J Exp Med2024; 221(9): e20231314.
9.
MaKDuWWangX, et al.Multiple functions of B cells in the pathogenesis of systemic lupus erythematosus. Int J Mol Sci2019; 20(23): 6021.
10.
ParodisILongXKarlssonMCI, et al.B cell tolerance and targeted therapies in SLE. J Clin Med2023; 12(19): 6268.
11.
KarrarSCunninghame GrahamDS. Abnormal B cell development in systemic lupus erythematosus: what the genetics tell us. Arthritis Rheumatol2018; 70(4): 496–507.
12.
Merino-VicoAFrazzeiGvan HamburgJP, et al.Targeting B cells and plasma cells in autoimmune diseases: from established treatments to novel therapeutic approaches. Eur J Immunol2023; 53(1): e2149675.
13.
PapavassiliouKAPapavassiliouAG. Transcription factor drug targets. J Cell Biochem2016; 117(12): 2693–2696.
14.
GhoshDPapavassiliouAG. Transcription factor therapeutics: long-shot or lodestone. Curr Med Chem2005; 12(6): 691–701.
15.
SundararajSCasarottoMG. Molecular interactions of IRF4 in B cell development and malignancies. Biophys Rev2021; 13(6): 1219–1227.
16.
WangHLeeCHQiC, et al.IRF8 regulates B-cell lineage specification, commitment, and differentiation. Blood2008; 112(10): 4028–4038.
17.
LongCXuQBDingL, et al.Triptolide inhibits human telomerase reverse transcriptase by downregulating translation factors SP1 and c-Myc in epstein-barr virus-positive B lymphocytes. Oncol Lett2021; 21(4): 280.
18.
WangHJainSLiP, et al.Transcription factors IRF8 and PU.1 are required for follicular B cell development and BCL6-driven germinal center responses. Proc Natl Acad Sci U S A2019; 116(19): 9511–9520.
19.
LiGHaoWHuW. Transcription factor PU.1 and immune cell differentiation (review). Int J Mol Med2020; 46(6): 1943–1950.
20.
WillisSNTellierJLiaoY, et al.Environmental sensing by mature B cells is controlled by the transcription factors PU.1 and SpiB. Nat Commun2017; 8(1): 1426.
21.
BatistaCRLiSKXuLS, et al.PU.1 regulates Ig light chain transcription and rearrangement in Pre-B cells during B cell development. J Immunol2017; 198(4): 1565–1574.
22.
ZhouNLiuKSunY, et al.Transcriptional mechanism of IRF8 and PU.1 governs microglial activation in neurodegenerative condition. Protein Cell2019; 10(2): 87–103.
UenoNNishimuraNUenoS, et al.PU.1 acts as tumor suppressor for myeloma cells through direct transcriptional repression of IRF4. Oncogene2017; 36(31): 4481–4497.
25.
PangSHMinnichMGangatirkarP, et al.PU.1 cooperates with IRF4 and IRF8 to suppress pre-B-cell leukemia. Leukemia2016; 30(6): 1375–1387.
26.
OkunoYYukiH. PU.1 is a tumor suppressor for B cell malignancies. Oncotarget2012; 3(12): 1495–1496.
27.
Garrett-SinhaLASuGHRaoS, et al.PU.1 and Spi-B are required for normal B cell receptor-mediated signal transduction. Immunity1999; 10(4): 399–408.
28.
OppenheimALahavG. The puzzling interplay between p53 and Sp1. Aging (Albany NY)2017; 9(5): 1355–1356.
29.
SilvaGMarinsMFachinAL, et al.Anti-cancer activity of trans-chalcone in osteosarcoma: involvement of Sp1 and p53. Mol Carcinog2016; 55(10): 1438–1448.
30.
O'ConnorLGilmourJBoniferC. The role of the ubiquitously expressed transcription factor Sp1 in tissue-specific transcriptional regulation and in disease. Yale J Biol Med2016; 89(4): 513–525.
31.
WilsonASPowerBEMolloyPL. DNA hypomethylation and human diseases. Biochim Biophys Acta2007; 1775(1): 138–162.
32.
SekigawaIOkadaMOgasawaraH, et al.DNA methylation in systemic lupus erythematosus. Lupus2003; 12(2): 79–85.
33.
FulcinitiMAminSNanjappaP, et al.Significant biological role of sp1 transactivation in multiple myeloma. Clin Cancer Res2011; 17(20): 6500–6509.
34.
SmithELShmerlingRH. The American college of rheumatology criteria for the classification of systemic lupus erythematosus: strengths, weaknesses, and opportunities for improvement. Lupus1999; 8(8): 586–595.
35.
MotaPReddyVIsenbergD. Improving B-cell depletion in systemic lupus erythematosus and rheumatoid arthritis. Expet Rev Clin Immunol2017; 13(7): 667–676.
36.
SokalskiKMLiSKWelchI, et al.Deletion of genes encoding PU.1 and Spi-B in B cells impairs differentiation and induces pre-B cell acute lymphoblastic leukemia. Blood2011; 118(10): 2801–2808.
37.
MaffeiRFiorcariSAteneCG, et al.The dynamic functions of IRF4 in B cell malignancies. Clin Exp Med2023; 23(4): 1171–1180.
38.
FangYChenWLiZ, et al.The role of a key transcription factor PU.1 in autoimmune diseases. Front Immunol2022; 13: 1001201.
39.
LioCWZhangJGonzález-AvalosE, et al.Tet2 and Tet3 cooperate with B-lineage transcription factors to regulate DNA modification and chromatin accessibility. eLife2016; 5: e18290.
40.
BarwickBGScharerCDMartinezRJ, et al.B cell activation and plasma cell differentiation are inhibited by de novo DNA methylation. Nat Commun2018; 9(1): 1900.
41.
OikawaTYamadaTKihara-NegishiF, et al.The role of ets family transcription factor PU.1 in hematopoietic cell differentiation, proliferation and apoptosis. Cell Death Differ1999; 6(7): 599–608.
42.
AboeleneinHRHamzaMTMarzoukH, et al.Reduction of CD19 autoimmunity marker on B cells of paediatric SLE patients through repressing PU.1/TNF-α/BAFF axis pathway by miR-155. Growth Factors2017; 35(2-3): 49–60.
43.
XiangNFangXSunXG, et al.Expression profile of PU.1 in CD4(+)T cells from patients with systemic lupus erythematosus. Clin Exp Med2021; 21(4): 621–632.
44.
MarksSDTullusK. Modern therapeutic strategies for paediatric systemic lupus erythematosus and lupus nephritis. Acta Paediatr2010; 99(7): 967–974.
45.
NamSLimJS. Essential role of interferon regulatory factor 4 (IRF4) in immune cell development. Arch Pharm Res (Seoul)2016; 39(11): 1548–1555.
46.
De SilvaNSSimonettiGHeiseN, et al.The diverse roles of IRF4 in late germinal center B-cell differentiation. Immunol Rev2012; 247(1): 73–92.
47.
ShengYZhangJLiK, et al.Bach2 overexpression represses Th9 cell differentiation by suppressing IRF4 expression in systemic lupus erythematosus. FEBS Open Bio2021; 11(2): 395–403.
48.
XiaoZXLiangROlsenN, et al.Roles of IRF4 in various immune cells in systemic lupus erythematosus. Int Immunopharmacol2024; 133: 112077.
49.
MoormanHRReateguiYPoschelDB, et al.IRF8: mechanism of action and health implications. Cells2022; 11(17): 2630.
50.
SalemSSalemDGrosP. Role of IRF8 in immune cells functions, protection against infections, and susceptibility to inflammatory diseases. Hum Genet2020; 139(6-7): 707–721.
51.
PathakSMaSShuklaV, et al.A role for IRF8 in B cell anergy. J Immunol2013; 191(12): 6222–6230.
52.
ZhouTZhuXYeZ, et al.Lupus enhancer risk variant causes dysregulation of IRF8 through cooperative lncRNA and DNA methylation machinery. Nat Commun2022; 13(1): 1855.
53.
BeckerAMDaoKHHanBK, et al.SLE peripheral blood B cell, T cell and myeloid cell transcriptomes display unique profiles and each subset contributes to the interferon signature. PLoS One2013; 8(6): e67003.
54.
TianHPLunSMHuangHJ, et al.DNA methylation affects the SP1-regulated transcription of FOXF2 in breast cancer cells. J Biol Chem2015; 290(31): 19173–19183.
55.
DouetVHellerMBLe SauxO. DNA methylation and Sp1 binding determine the tissue-specific transcriptional activity of the mouse Abcc6 promoter. Biochem Biophys Res Commun2007; 354(1): 66–71.
56.
BeishlineKAzizkhan-CliffordJ. Sp1 and the ‘hallmarks of cancer’. FEBS J2015; 282(2): 224–258.
57.
LinRKWuCYChangJW, et al.Dysregulation of p53/Sp1 control leads to DNA methyltransferase-1 overexpression in lung cancer. Cancer Res2010; 70(14): 5807–5817.
58.
ShaoKMShaoWH. Transcription factors in the pathogenesis of lupus nephritis and their targeted therapy. Int J Mol Sci2024; 25(2): 1084.
59.
ChaeYMParkKKLeeIK, et al.Ring-Sp1 decoy oligonucleotide effectively suppresses extracellular matrix gene expression and fibrosis of rat kidney induced by unilateral ureteral obstruction. Gene Ther2006; 13(5): 430–439.
60.
OelznerPAbendrothKHeinG, et al.Predictors of flares and long-term outcome of systemic lupus erythematosus during combined treatment with azathioprine and low-dose prednisolone. Rheumatol Int1996; 16(4): 133–139.
61.
GlassDRTsaiAGOliveriaJP, et al.An integrated multi-omic single-cell atlas of human B cell identity. Immunity2020; 53(1): 217–232.
62.
SongSZhangJ-YLiuF-Y, et al.B cell subsets-related biomarkers and molecular pathways for systemic lupus erythematosus by transcriptomics analyses. Int Immunopharmacol2023; 124: 110968.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
